Johnson & Johnson

CRO Evotec sees spin-out firm as strategic opportunity

Image: iStock/ArielMieli

Evotec’s auto-immune spin-out Topas represents “a strategic opportunity” for the CRO, which reported strong first quarter sales this week.

Novartis JV helps virtual trial CRO to $6.5m fundraising round

Novartis joint venture helps virtual trial CRO to $6.5m fundraising round

Bavarian Nordic's headquarters in Kvistgaard, Denmark

Bavarian Nordic wins up to $33m to develop J&J Ebola vaccine

Research consortium looks to identify biomarkers for autism treatments

Research consortium looks to identify biomarkers for autism treatments

Brazil's ANVISA is a hands-on auditor, says CMO Kemwell

Exporting to Brazil? ANVISA is tough and hands-on, says Kemwell

Antiquated clinical trial industry ripe for change from innovation, experts say

Antiquated clinical trial industry ripe for change from innovation, experts say

Biologics demand a boon for CMOs, but a shift to single-use could see more competition

Bio-CMO sector to grow over 40% on Big Biopharma's burgeoning pipelines

$100m Big Pharma-backed VC fund to focus on dementia research

$100m Big Pharma-backed VC fund to focus on dementia research

Brian Cass, Huntingdon CEO

Preclinical prices improving says Huntingdon CEO; firm is mulling US capacity expansion

Four hepatitis C treatments have been launched in the US over the past year, boosting revenues for distributor and wholesaler AmeriSourceBergen

HCV drugs Sovaldi and Olysio boost Q1 sales for AmeriSourceBergen

More Johnson & Johnson